Clinical Trial Update: Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk [Phase 2]

View source ↗

Summary

A Phase 2 trial led by UNICANCER is evaluating whether the duration of endocrine therapy can be shortened in women with HR-positive, HER2-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: UNICANCER | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING